Indication

In combination with obinutuzumab (VenG) is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

Medicine details

Medicine name:
venetoclax (Venclyxto)
SMC ID:
SMC2293
Pharmaceutical company
AbbVie Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
07 December 2020
SMC meeting date:
03 November 2020
Patient group submission deadline:
07 September 2020